IBO — IMPACT BIOMEDICAL INC.

—
NYSE · Health Care · Pharmaceuticals · CIK 1834105 ·
Last close
$6.17
Market Cap
$53.31M
52W High
$10.51
52W Low
$2.43
ADV30
15,916
Next earnings
—
Impact BioMedical Inc. discovers, develops, and commercializes products and technologies to address unmet needs in human healthcare and wellness for specialty biopharmaceuticals, antivirals, antimicrobials, consumer healthcare, and wellness products in the United States. The company provides Linebacker, a platform of small molecule electrophilically enhanced polyphenol compounds with application in oncology, inflammatory disorders, and neurology; and Laetose technology that is derived from a unique combination of sugar and inositol, which can inhibit the inflammatory and metabolic response of sugar alone. It also develops functional fragrance formulation, a suite of functional fragrances containing specialized botanical ingredients with application as an antimicrobial, and as an additive in insect repellents, detergents, lotions, shampoo, fabrics, and other substances. In addition, the company develops Equivir/Equivir G technology, a novel blend of polyphenols, which have demonstrated antiviral effects for use as health supplements and medications. Further, it is developing 3F (functional fragrance formulation), a formulation of botanical ingredients. Impact BioMedical Inc. was incorporated in 2018 and is based in Houston, Texas. Impact BioMedical Inc. operates as a subsidiary of DSS BioHealth Security, Inc.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 21,000 15,000 -648,000 -645,000 16,427,000 21,000 3,061,000
Jun 2026 3,000 2,000 -702,000 -699,000 16,745,000 10,000 2,733,000
Mar 2026 7,000 — -2,289,000 -2,287,000 17,086,000 20,000 2,375,000
Dec 2025 7,000 -415,000 -1,158,000 5,245,000 17,405,000 3,000 1,850,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$116,000
Investing CF
$2,000
Financing CF
$373,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.98
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-53,139,000
Inventory
$56,000
Receivables
$14,000
ST Investments
—
EBIT TTM
$-973,000
Pretax Income TTM
$-973,000
Interest Exp TTM
$0
Analysts
—

Yahoo Snapshot (yfinance, live)

Total Revenue
$38,000
EBITDA
$-4,225,000
Free Cash Flow
$436,500
Enterprise Value
$47,635,600
Total Cash
$21,000
Total Debt
$0
Shares Out
8,640,000
Trailing EPS
$11.11
Book Value
$1.52
ROE
71.2%
ROA
-17.3%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 5y)

Revenues vs Net Income (last 5y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 32,000 -4,270,000 -11,838,000 17,405,000 1,850,000 12,609,000 -1,890,000
Dec 2024 0 -3,397,000 -24,708,000 20,290,000 13,053,000 4,259,000 -2,854,000
Dec 2023 0 -4,028,000 -4,336,000 44,633,000 16,371,000 25,222,000 -2,851,000
Dec 2022 50,000 -3,404,000 -7,051,000 46,497,000 13,828,000 29,558,000 -2,242,000
Dec 2021 — — — — — — —

TTM Snapshot

Revenues TTM
$35,000
NetIncome TTM
$789,000
OpCashFlow TTM
—
Assets (Latest)
$16,745,000
Forward EPS
—

Peers — same industry

TickerNameMarket CapLastDaily %
XLO Xilio Therapeutics, Inc. $53.26M $7.54 —
HRTX HERON THERAPEUTICS, INC. /DE/ $53.70M $0.28 —
IBIO iBio, Inc. $52.71M $0.75 —
VRCA Verrica Pharmaceuticals Inc. $53.94M $3.14 —
GANX Gain Therapeutics, Inc. $52.54M $1.18 —

News headlines (Yahoo Finance, 1h cache)

DSS Announces Completion of Impact Biomedical Business Combination with Zoar Limited
2026-11-18 13:05 · Yahoo
Zoar Limited Completes Business Combination with Impact Biomedical Inc.
2026-11-18 13:00 · Yahoo
DSS, Inc. Announces SEC Declaration of Effectiveness of Form F-4 Registration Statement, Marking Major Milestone Toward Closing of Proposed Business Combination
2026-11-03 04:33 · Yahoo
Impact Biomedical Inc. and Zoar Limited Announce SEC Declaration of Effectiveness of Form F-4 Registration Statement, Marking Major Milestone Toward Closing of Proposed Business Combination
2026-11-03 04:25 · Yahoo
DSS, Inc. Announces Form F-4 Filing in Connection with Impact Biomedical’s Proposed Business Combination with Zoar Limited
2026-09-16 13:25 · Yahoo
Impact Biomedical Inc Announces Filing of Form F-4 Registration Statement in Connection with Proposed Merger with Zoar Ltd. (f/k/a Dr. Ashley’s Limited)
2026-09-16 13:20 · Yahoo
CORRECTED — Impact Biomedical Inc (NYSE: IBO) Announces 1 for 12.62 Reverse Stock Split to Pursue Completion of Merger with Zoar Limited (f/k/a Dr Ashleys Limited)
2026-09-15 01:26 · Yahoo
Impact BioMedical Inc (NYSE American: IBO) Announces 1 for 12.62 Reverse Stock Split to Pursue Completion of Merger with Zoar Ltd. (previously Dr. Ashley’s Ltd.)
2026-09-11 20:05 · Yahoo
Impact BioMedical Inc. Reports Going Concern Audit Opinion in 2025 10-K Filing While Continuing Strategic Merger Plans
2026-04-03 17:52 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.